Interestingly, SGT-53 seems to boost antitumor immunity and sensitize glioblastoma to anti-PD-1 (anti-programmed cell death protein 1) therapy by upregulating PD-L1 expression [107], while reducing immune-related adverse events [108]. Here, PDCD1 is linked to glioblastoma.